Adolor Corporation Receives Milestone Payment From Glaxosmithkline - Drug Expected to Relieve Itch Symptoms in Large Eczema Market -

Apr 04, 2001, 01:00 ET from Adolor Corp

    EXTON, Pa., April 4 /PRNewswire/ -- Adolor Corp (Nasdaq:   ADLR) announced
 today that it has received a milestone payment from GlaxoSmithKline as a
 result of a 1999 agreement for the development and commercial rights to
 topical formulations of ADL 2-1294, a peripheral opioid analgesic, for
 treatment of dermal conditions.  GlaxoSmithKline has developed a new
 formulation of ADL 2-1294 that will now move into Phase 2 dermatology clinical
 trials.
     "We have every reason to believe in the efficacy of this product candidate
 and we are eager to learn how this new dermal formulation of ADL 2-1294 will
 perform in the clinic," commented John Farrar, Ph.D., president and chief
 executive officer of Adolor Corporation.  "The next several months will be
 exciting, as we await the results."
     ADL 2-1294 is loperamide hydrochloride, a potent opioid receptor stimulant
 which does not cross the blood brain barrier and therefore is devoid of
 central nervous system side effects associated with the narcotic opioid
 analgesics such as morphine or codeine.
     Dermal ADL 2-1294 will be developed and marketed by GlaxoSmithKline.
 Santen Pharmaceutical Co Limited, Osaka, Japan is developing ADL 2-1294 for
 ophthalmic pain.  Adolor retains the rights to all additional products based
 on the ADL 2-1294 technology covered in the issued patents.
 
     About Adolor Corporation
     Adolor Corporation discovers, develops and plans to commercialize
 proprietary pharmaceutical products for the treatment of pain and to mitigate
 the side effects that are caused by current pain treatments.  Adolor has a
 portfolio of product candidates in development in Phase 1 to Phase 3 clinical
 trials. These products include our peripheral opioid analgesics and ADL
 8-2698, which is intended to reduce the most prevalent and severe side effects
 of current opioid narcotics, such as nausea and vomiting, as well as
 treat the symptoms of opioid-induced bowel dysfunction, such as constipation.
 Adolor's product candidates target peripheral opioid receptors and are not
 expected to exhibit the dose-limiting side effects of existing opioid
 narcotics.
 
     Certain statements made in this press release related to Adolor products,
 as well as any therapeutic applications and outcomes, may be deemed to be
 forward-looking statements.  Such statements involve risks and uncertainties.
 Among the factors that could cause actual results to differ materially from
 those set forth in these statements are the risk that the clinical trials for
 Adolor's product candidates may not be successful, Adolor may not obtain
 necessary regulatory approvals for its product candidates and the risks and
 other factors detailed, from time to time, in Adolor's filings with the
 Securities and Exchange Commission, including Adolor's Registration Statement
 on Form S-l.
 
     Note:  This press release is available at http://www.adolor.com.
 
 

SOURCE Adolor Corp
    EXTON, Pa., April 4 /PRNewswire/ -- Adolor Corp (Nasdaq:   ADLR) announced
 today that it has received a milestone payment from GlaxoSmithKline as a
 result of a 1999 agreement for the development and commercial rights to
 topical formulations of ADL 2-1294, a peripheral opioid analgesic, for
 treatment of dermal conditions.  GlaxoSmithKline has developed a new
 formulation of ADL 2-1294 that will now move into Phase 2 dermatology clinical
 trials.
     "We have every reason to believe in the efficacy of this product candidate
 and we are eager to learn how this new dermal formulation of ADL 2-1294 will
 perform in the clinic," commented John Farrar, Ph.D., president and chief
 executive officer of Adolor Corporation.  "The next several months will be
 exciting, as we await the results."
     ADL 2-1294 is loperamide hydrochloride, a potent opioid receptor stimulant
 which does not cross the blood brain barrier and therefore is devoid of
 central nervous system side effects associated with the narcotic opioid
 analgesics such as morphine or codeine.
     Dermal ADL 2-1294 will be developed and marketed by GlaxoSmithKline.
 Santen Pharmaceutical Co Limited, Osaka, Japan is developing ADL 2-1294 for
 ophthalmic pain.  Adolor retains the rights to all additional products based
 on the ADL 2-1294 technology covered in the issued patents.
 
     About Adolor Corporation
     Adolor Corporation discovers, develops and plans to commercialize
 proprietary pharmaceutical products for the treatment of pain and to mitigate
 the side effects that are caused by current pain treatments.  Adolor has a
 portfolio of product candidates in development in Phase 1 to Phase 3 clinical
 trials. These products include our peripheral opioid analgesics and ADL
 8-2698, which is intended to reduce the most prevalent and severe side effects
 of current opioid narcotics, such as nausea and vomiting, as well as
 treat the symptoms of opioid-induced bowel dysfunction, such as constipation.
 Adolor's product candidates target peripheral opioid receptors and are not
 expected to exhibit the dose-limiting side effects of existing opioid
 narcotics.
 
     Certain statements made in this press release related to Adolor products,
 as well as any therapeutic applications and outcomes, may be deemed to be
 forward-looking statements.  Such statements involve risks and uncertainties.
 Among the factors that could cause actual results to differ materially from
 those set forth in these statements are the risk that the clinical trials for
 Adolor's product candidates may not be successful, Adolor may not obtain
 necessary regulatory approvals for its product candidates and the risks and
 other factors detailed, from time to time, in Adolor's filings with the
 Securities and Exchange Commission, including Adolor's Registration Statement
 on Form S-l.
 
     Note:  This press release is available at http://www.adolor.com.
 
 SOURCE  Adolor Corp